MedPath

Metformin

Generic Name
Metformin
Brand Names
Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
Drug Type
Small Molecule
Chemical Formula
C4H11N5
CAS Number
657-24-9
Unique Ingredient Identifier
9100L32L2N
Background

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication

Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
-
Clinical Trials
Related News
cancer.gov
·

Hormone Therapy for Breast Cancer Fact Sheet

Hormones like estrogen and progesterone, produced by ovaries and other tissues, influence cell actions and can promote hormone-sensitive breast cancers. These cancers, containing hormone receptors, are treated by blocking hormone production or effects using drugs like SERMs, aromatase inhibitors, and GnRH agonists. Treatments vary by cancer stage and patient specifics, aiming to reduce recurrence and improve survival.
pegsummit.com
·

Poster Titles - PEGS Boston Summit

The article lists poster presentations for 2024, detailing research on immunocytokines, antibody engineering, cancer therapy, and biotherapeutic development. Topics include AI in drug design, antibody humanization, and novel therapeutic platforms, showcasing advancements in biotechnology and medicine.
pmc.ncbi.nlm.nih.gov
·

The cost-effectiveness of diabetes prevention

The study analyzed costs and outcomes of lifestyle, metformin, and placebo interventions in DPP and DPPOS, focusing on direct medical, non-medical, and indirect costs from health system and societal perspectives. It found lifestyle intervention delayed diabetes onset by 11 years, was cost-saving for under 45s, and cost-effective across ages. Metformin delayed onset by 3 years, was cost-effective for younger participants but less so for older. Cost-utility analyses used QALYs, with lifestyle costing $1,124 and metformin $31,286 per QALY gained versus placebo.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy